Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis

checkorphan
Learn more about:
Adenomyosis
Related Clinical Trial
The Use of Shear Wave Elastography, Transvaginal Ultrasound and Pelvic MRI in the Diagnosis of Adenomyosis Long-term Use of Mifepristone in the Treatment of Adenomyosis Radiofrequency Ablation of Adenomyosis Determination of the Incidence of Endometriosis and or Adenomyosis in Patients Diagnosed With Polycystic Ovary Syndrome, or the Incidence of Polycystic Ovary Syndrome in Patients Diagnosed With Endometriosis and or Adenomyosis The Effect of Adenomoyosis on Pregnancy Outcomes Observational Study of Patients Suffering From Endometriosis and Adenomyosis Factors Associated With Adenomyosis and a Clinical Scoring System for the Diagnosis Quality of Life After Hysterectomy (AdenoQOL) Low Molecular Weight Heparin on the Adenomyosis Patients’IVF-ET Outcome Diagnosis of Adenomyosis Using Ultrasound, Elastography and MRI Clinical and Molecular Study of Endometriosis and Adenomyosis Surgical Success After Laparoscopic vs Abdominal Hysterectomy Electronic Catheter Stethoscope Ovarian Reserve Modification After Lps Hysterectomy With Bilateral Salpingectomy Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Uterine Artery Embolization for Symptomatic Fibroids Oxytocin in MRI-HIFU To Compare to 2-channel and Multiple-channel Single Port Laparoscopic-assisted Vaginal Hysterectomy Effect of Addition of Steroids on Duration of Analgesia Paracervical Block in Laparoscopic Hysterectomy Use of Dexamethasone in Uterine Artery Embolization Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU) Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS) Dienogest for Treatment of Adenomyotic Uteri Health-Related QoL Among Women Receiving Hysterectomy in NTUH Development and Validation of EHP-30 (Hong Kong Chinese Version) for Patients With Endometriosis and Adenomyosis Adenomyosis and Ulipristal Acetate Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis LNG-IUS for Treatment of Dysmenorrhea Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Adenomyosis: Genomic Mechanisms and Biological Response What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Comparing Efficacy of Microwave vs Embolization Treatment for Adenomyosis Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis A Prospective Study of Diagnostic Accuracy of Ultrasound Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis A Multi-omics Study of Adenomyosis Norwegian Adenomyosis Study II: Gene Expression Profiling of Adenomyosis Levonorgestrel Intrauterine System and Adenomyosis Validation of the Adenomyosis Calculator Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri Modified Downregulation for Women With Adenomyosis of the Uterus Prior to Frozen-thawed Embryo Transfer. New Inflammation Markers for Distinguishing Uterine Adenomyosis and Leiomyoma The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms High-intensity Focused Ultrasound in Treatment of Uterine Adenomyosis Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis Norwegian Adenomyosis Study III: Peristalsis Histopathological Diagnosis of Adenomyosis Norwegian Adenomyosis Study I Vaginal Bromocriptine for Treatment of Adenomyosis Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis

Brief Title

Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis

Official Title

Benefit of Gonadotropin-releasing Hormone (GnRH) Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and / or Adenomyosis: Randomized Prospective Study

Brief Summary

      Women suffering from endometriosis and/or adenomyosis may also suffer from infertility. GnRH
      agonist injection could improve implantation and therefore increase the pregnancy rate in
      these patients. This study was designed to evaluate effects of the additional of GnRH agonist
      (single or 2 doses) to the routine oestrogens and progestins use as support before Frozen
      Embryon Transfer as compared to oestrogens and progestins only.

Detailed Description

      Endometriosis reveals the presence of glands or endometrial stroma outside the uterus,
      responsible for pain and infertility. Adenomyosis illustrates an invagination of endometrial
      islets within the myometrium, leading to a disturbance of its contractile activity, also
      potentiated by local hyperestrogenism.

      These two pathologies are often associated, and express an alteration of the eutopic
      endometrium by pro-inflammatory markers responsible for a lower implantation rate.

      GnRH agonists are known to decrease these pro-inflammatory markers (cytochrome P450 and Cox 2
      aromatase) in the eutopic endometrium of women with endometriosis or adenomyosis.

      Patients will received 1 or 2 injection of GnRH delay agonist (Decapeptyl 3mg) approximately
      1 month before the frozen embryo transfer.

Study Phase

Phase 2/Phase 3

Study Type

Interventional

Primary Outcome

Clinical pregnancy rate in both groups at last visit ultrasound

Secondary Outcome

 Successful implantation rate on the number of patients included

Condition

Endometriosis

Intervention

GnRH agonist

Study Arms / Comparison Groups

 Frozen embryo transfer with Hormonal Replacement Therapy (HRT)
Description:  Patient will received usual Hormonal Replacement Therapy for a Frozen embryo transfer composed of estrogens and progestins.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Drug

Estimated Enrollment

180

Start Date

March 18, 2021

Completion Date

January 1, 2023

Primary Completion Date

January 1, 2023

Eligibility Criteria

        Inclusion Criteria:

          -  Women aged 18 to 36 years (women ≥18 years to <36 years) with endometriosis and / or
             adenomyosis

          -  Having benefited from In vitro fertilisation /intracytoplasmic micro-injection with
             freeze all and for whom the frozen embryon transfer of a blastocyst is planned

          -  A normal uterine cavity

          -  An MRI showing endometriosis and / or adenomyosis during the inclusion visit

          -  Having signed a consent form

          -  Being affiliated to a Health Insurance Plan.

        Exclusion Criteria:

          -  Patient aged <18 years and ≥ 36 years

          -  BMI> 35

          -  History of implantation failures (≥ 2)

          -  Endometrial alterations: synechiae, polyps, myomas, hyperplasia, hematometra

          -  known hydrosalpinx uni or bilateral

          -  MRI showing no endometriosis or adenomyosis

          -  Hypersensitivity to GnRH, GnRH analogues, or any of the excipients of Decapeptyl 3 mg

          -  Known hypersensitivity to estradiol

          -  Known hypersensitivity to progesterone

          -  Known hypersensitivity to acetylsalicylic acid or other nonsteroidal anti-inflammatory
             drugs

          -  Known hypersensitivity to folic acid

          -  Known hypersensitivity to cefixime or an antibiotic in the cephalosporin group

          -  Known hypersensitivity to levofloxacin or any other quinolone

          -  History of tendinopathies related to the administration of fluoroquinolones

          -  Epilepsy

          -  Hypersensitivity to contrast agents for MRI

          -  Known or suspected breast cancer or history of breast cancer

          -  Known or suspected genital tract cancer or history of genital cancer

          -  known or suspected estrogen-dependent malignant neoplasms

          -  Undiagnosed genital haemorrhage

          -  Untreated endometrial hyperplasia

          -  History of idiopathic venous thrombo-embolic accident or evolving venous
             thrombo-embolic event (deep vein thrombosis, pulmonary embolism)

          -  Recent or evolving arterial thromboembolic stroke (eg angina, myocardial infarction)

          -  Acute liver disease or history of liver disease, until hepatic tests are normalized

          -  Severe renal insufficiency

          -  Severe, uncontrolled heart failure

          -  Evolutionary gastroduodenal ulcer

          -  History of asthma caused by the administration of salicylates or substances of similar
             activity, especially nonsteroidal anti-inflammatory drugs

          -  GnRH Agonist Decapeptyl administered within 6 months prior to transfer

          -  To be deprived of liberty or under guardianship

          -  Pregnancy and breast feeding.

Gender

Female

Ages

18 Years - 36 Years

Accepts Healthy Volunteers

No

Contacts

Jean-Marc Ayoubi, Pr, 0033146251175, [email protected]

Location Countries

France

Location Countries

France

Administrative Informations

NCT ID

NCT04356664

Organization ID

2019_0012

Responsible Party

Sponsor

Study Sponsor

Hopital Foch

Study Sponsor

Jean-Marc Ayoubi, Pr, Principal Investigator, Hopital Foch

Verification Date

August 2022